Mikhail Blagosklonny is a scientist that is involved in cancer research and aging. Mikhail Blagosklonny is currently a professor of oncology at the esteemed Roswell Park Cancer Institute, a position he was appointed to in 2009. Blagosklonny obtained his M.D in internal medicine from Pavlov State Medical University of St. Peterburg. He also received his PhD in experimental medicine and cardiology from the same university. During his career Blagosklonny has researched and investigated many different avenues regarding cancer and its devastating effects.
He has developed theories and approaches that can one day revolutionize cancer treatment. Mikhail Blagosklonny has a broad range of research interests, from molecular and cellular biology to clinical investigations. Some of his research is specifically inclusive of cell cycle, apoptosis, mitosis, signal transduction, oncogenes and tumor suppressors. Blagosklonny, because of his in-depth research has become a strong advocate for the use of Rapamycin a possible life extending drug in the fight against cancer and has a strong hypothesis regarding the role of TOR signaling in cancer and aging.
Rapamycin in regards to cancer seems to suppress tumors and is known to increase lifespan in mice. Targeted cancer therapies that do not target healthy cells are of special interest in his research. Before Mikhail Blagosklonny’s position at Roswell Park Cancer Institute, Blagosklonny previously held positions as Associate Professor of medicine at New York Medical College, Valhalla, NY and Senior Scientist at Ordway Research Institute, Albany, NY. Mikhail Blagosklonny has published 300 research articles including reviews and book chapters.
He is the editor of several publications including Cell cycle, and Aging both of which he was editor and chief. He was also a member of the editorial board for Cell Death and Differentiation and was associate editor of Cancer Biology and Therapy. Mikhail Blagosklonny is also the author of anti-cancer approaches also known as chemotherapeutic engineering and cell cyclotherapy. He continues to aid in the fight against cancer with his dedication to performing innovative and groundbreaking research. View his LinkedIn profile.